Figure 2

Serum biomarker analysis of neoadjuvant chemotherapy for locally advanced breast cancer according to pathologic response. (a) Serum levels of epidermal growth factor receptor (EGFR), soluble Fas ligand (sFasL), migration inhibitory factor (MIF), and MMP-2 measured prior to the second round of neoadjuvant chemotherapy (NAC) in 27 patients achieving a pathologic complete response (pCR) or partial pathologic response (pPR) and 16 patients demonstrating no response (NR) to NAC. (b) Cumulative receiver operating characteristics for patients achieving a pCR or pPR versus nonresponders to NAC based on serum levels of ErbB2, EGFR, MIF, MMP-2, and CD40 measured prior to the second cycle of NAC. Statistical significance: *P < 0.05.